drugset / Trial / NCT03414684
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
Phase 2
Active not recruiting
78 enrolled
Dana-Farber Cancer Institute
Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body. The interventions involved in this study are: * Carboplatin * Nivolumab
Timeline
- Start
- 2018-01-30
- Primary completion
- 2021-09-28
- Completion
- 2026-07-30
Outcome
Missed primary endpoint
registry p = 0.88; Hazard Ratio (HR) 0.95 (95% CI 0.49 to 1.84); Log Rank NCT03414684 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 360 mg | Intravenous |